[Parlodel in early combination with levodopa in the treatment of Parkinson disease. Comparison of 2 dosage forms].
In order to compare two titrations of Parlodel in early combination with levodopa in the treatment of Parkinson's disease a multicentre randomized open study was performed with a fast titration in group A (15 mg/day for 3 weeks) and slow in group B (15 mg/day for 5 weeks). 153 patients were included: 77 in group A and 76 in group B. The recommended titration was observed in 76% in group A and 88% in group B, the difference was not significant. The efficacy assessed by the Webster Scale was remarkable and similar in the two groups. This study confirms the additive benefit of bromocriptine on the symptoms and long term complications of levodopa therapy, but no absolute conclusion can be drawn regarding the best titration.
Goulley
F
F
Laboratoires Sandoz, Groupe Thérapeutique Neuropsychiatrie, Rueil Malmaison.
Wolmark
Y
Y
Bourdeix
I
I
Chaumet-Riffaud
P D
PD
D000368:Aged; D000369:Aged, 80 and over; D001971:Bromocriptine / Q000008:administration & dosage / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D015259:Dopamine Agents; D001971:Bromocriptine; D007980:Levodopa
Introduction du Parlodel en association précoce à la lévodopa dans le traitement de la maladie de Parkinson. Comparaison de deux progressions posologiques.